Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report ; volume:15 ; number:1 ; day:23 ; month:4 ; year:2021 ; pages:1-7 ; date:12.2021
Journal of medical case reports ; 15, Heft 1 (23.4.2021), 1-7, 12.2021
- Urheber
-
Kikuchi, Fumi
Saheki, Takanobu
Imachi, Hitomi
Kobayashi, Toshihiro
Fukunaga, Kensaku
Ibata, Tomohiro
Sato, Seisuke
Ban, Natsuki
Lyu, Jingya
Japar, Salimah
Murao, Koji
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13256-020-02656-7
- URN
-
urn:nbn:de:101:1-2021061021134529694188
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kikuchi, Fumi
- Saheki, Takanobu
- Imachi, Hitomi
- Kobayashi, Toshihiro
- Fukunaga, Kensaku
- Ibata, Tomohiro
- Sato, Seisuke
- Ban, Natsuki
- Lyu, Jingya
- Japar, Salimah
- Murao, Koji
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Low-dose nivolumab in advanced hepatocellular carcinoma
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Low-dose nivolumab in advanced hepatocellular carcinoma
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Low-dose nivolumab in advanced hepatocellular carcinoma
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma